NON-SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON-SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Zapping growing tumors early may buy more time for metastatic cancer patients
Disease control OngoingThis study looks at whether giving precise radiation (SBRT) to tumors that have just started to grow can help people with metastatic triple-negative breast cancer or non-small cell lung cancer live longer without their disease getting worse. About 107 adults are taking part. The …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
New drug combo targets Hard-to-Treat liver and lung cancers
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and bevacizumab, in people with liver cancer or lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control. Researchers will collect blood and tumor samples to understand how the d…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
Triple threat: new combo aims to extend life in advanced lung cancer
Disease control OngoingThis phase 3 trial tests whether adding radiation to a standard immunotherapy-plus-chemotherapy regimen can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive pembrolizumab and chemotherapy, with or …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New hope for lung cancer patients after immunotherapy fails
Disease control OngoingThis study tests a combination of three drugs (bevacizumab, nab-paclitaxel, and platinum) as a second treatment for people with advanced non-small cell lung cancer that does not have certain gene changes and has gotten worse after first-line immunotherapy. The goal is to see if t…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 07:52 UTC
-
New hope for hard-to-treat lung cancer: targeted drug shows promise in late-stage trial
Disease control OngoingThis study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. The main goal is to see if the drug can shrink tumors. About 277 participants wi…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
New antibody takes aim at two cancer drivers in advanced tumors
Disease control OngoingThis study tests an experimental drug called MCLA-129 in people with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c-MET) at…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New hope for rare lung cancer mutations: targeted pill shows promise
Disease control OngoingThis study tests a daily pill called dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR gene mutations. The goal is to see if the drug shrinks tumors and controls the disease. Participants take the drug until their cancer worsens or they no l…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New hope for tough lung cancers: experimental drug combo tested
Disease control OngoingThis trial tests a new drug called acasunlimab (GEN1046), either alone or with another cancer drug (pembrolizumab), in people with advanced non-small cell lung cancer that came back or didn't respond to standard treatments. About 125 adults will receive the drugs intravenously ev…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Can timing of immunotherapy boost lung cancer outcomes?
Disease control OngoingThis study tests two different schedules of combining the immunotherapy drug durvalumab with standard chemotherapy (pemetrexed and carboplatin) in adults with advanced non-squamous non-small cell lung cancer. The goal is to see if staggering the doses improves how well the cancer…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Lung cancer showdown: which drug combo works best for TTF-1 negative patients?
Disease control OngoingThis study compares two different drug combinations as first treatments for people with a specific type of advanced lung cancer (TTF-1 negative). About 136 patients will be randomly assigned to one of two treatment groups. The goal is to see which combination helps patients live …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE4 • Sponsor: Nikolaj Frost MD • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Triple-Drug cocktail shows promise in tough lung cancer
Disease control OngoingThis study tests whether combining three drugs—nivolumab, ipilimumab, and nintedanib—can shrink tumors in people with advanced non-small cell lung cancer that cannot be cured. About 66 adults with no other treatment options will receive the drugs to see if the combination is safe…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
New hope for lung cancer patients whose tumors outsmart First-Line drugs
Disease control OngoingThis study tests a drug called lorlatinib in people with a rare, advanced lung cancer (ROS1-positive non-small cell lung cancer) that stopped responding to initial targeted therapy. About 54 participants will receive lorlatinib to see if it can shrink tumors and delay cancer grow…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain gene changes (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can shr…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Hope for older lung cancer patients: immunotherapy combo under study
Disease control OngoingThis study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemo alone or chemo plus atezolizumab. The goal is to see…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Computer nudge aims to speed up lung cancer treatment decisions
Knowledge-focused OngoingThis study looks at whether an electronic health record alert can help doctors order genetic tests for people newly diagnosed with advanced non-small cell lung cancer before they start treatment. About 260 patients from several Penn Medicine locations will take part. The goal is …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Charu Aggarwal • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC